Justin Elder, DO
Facial Plastic Surgery · Lewes, DENPI 1821223413
Payments from drug & device makers
Across 47 payments — averaging $32.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurent Medical Limited$393
- Aerin Medical Inc.$338
- Regeneron Healthcare Solutions, Inc.$164
- Amgen$97
- Inspire Medical Systems, Inc.$93
- Baxter Healthcare$76
- plus $374 from 12 others
What the payments were for
- Food & beverage$1,45995%
- Other$765%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurent Medical Limited | 13 | $393 |
| Aerin Medical Inc. | 6 | $338 |
| Regeneron Healthcare Solutions, Inc. | 8 | $164 |
| Amgen | 1 | $97 |
| Inspire Medical Systems, Inc. | 2 | $93 |
| Baxter Healthcare | 1 | $76 |
| Acclarent, Inc | 3 | $68 |
| Axogen | 1 | $67 |
| Medtronic | 2 | $66 |
| Sanofi | 2 | $40 |
| Smith+Nephew | 1 | $21 |
| Alk-abello, Inc | 1 | $20 |
| Stryker | 1 | $20 |
| Mallinckrodt Enterprises LLC | 1 | $19 |
| Novartis | 1 | $16 |
| Olympus America Inc. | 1 | $15 |
| Omeros Corporation | 1 | $12 |
| Mission Pharmacal Company | 1 | $11 |
How this compares
Too few facial plastic surgery providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine-FluticasoneAzelastine/Fluticasone | 55 | $13,386 |
| Ipratropium Bromide | 226 | $10,825 |
| Fluticasone Propionate | 217 | $4,757 |
| Montelukast Sodium | 204 | $4,373 |
| Levocetirizine Dihydrochloride | 162 | $4,308 |
| Azelastine Hcl | 70 | $2,880 |
| Mometasone Furoate | 25 | $2,573 |
| Omeprazole | 72 | $1,509 |
| Famotidine | 110 | $1,440 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 12 | $1,135 |
| Fluocinolone Acetonide Oil | 31 | $1,111 |
| Ofloxacin | 72 | $1,049 |
| Doxycycline Hyclate | 51 | $609 |
| Clotrimazole | 17 | $396 |
| Pantoprazole Sodium | 27 | $387 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.